Acyclic Carbon To Carbon Unsaturation Patents (Class 514/733)
-
Publication number: 20090035237Abstract: An emulsion cosmetic composition comprising at least one resveratrol derivative, an aqueous phase, and an oil phase, having at least one silicone surfactant, and a method for preparing emulsions capable of delivering active resveratrol to the skin.Type: ApplicationFiled: May 27, 2008Publication date: February 5, 2009Inventors: Daniel H. Maes, Fatemeh Mohammadi, Lisa Qu, Anna Czarnota, Thomas Mammone, Lieve Declercq, Julius R. Zecchino
-
Publication number: 20090029944Abstract: Adding fatty acids to agents enhances deliverability of the antioxidant, making the agent less likely to be degraded prior to intercellular delivery. Additionally, adding fatty acids to agents provides a time lapse-type mechanism to the agents. Fatty acid modified agents are made with a novel process in aqueous solution, reducing the need to use organic solvents. Agents that can be modified as disclosed herein include nearly any biological molecule that have hydroxyl, amine, or sulphydryl sites, including antioxidants, such as glutathione and polyphenols (e.g., ECGC, curcumin, or resveratol), saccharides, such as glucosamine, and other glycans.Type: ApplicationFiled: June 19, 2008Publication date: January 29, 2009Inventor: Keith K. Skinner
-
Publication number: 20090012183Abstract: A food product comprising from 0.05 to 1 wt % of trans-resveratrol can advantageously be used to control blood pressure. Preferred food products are spreads or drinks.Type: ApplicationFiled: July 2, 2008Publication date: January 8, 2009Inventors: Richard Draijer, Ferdinand Alexander Van Dorsten, Jozef Gabriel Rita De Mey
-
Publication number: 20090005461Abstract: Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not been studied as extensively as ?9-tetrahydrocannabinol (THC). The present disclosure reports the immunosuppressive properties of CBD and demonstrates that CBD induces apoptosis in thymocytes and splenocytes and inhibits the proliferative responsiveness of T and B cells. This indicates that CB2 selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents.Type: ApplicationFiled: June 18, 2008Publication date: January 1, 2009Applicant: University of South CarolinaInventors: Prakash S. Nagarkatti, Mitzi Nagarkatti
-
Publication number: 20090005443Abstract: There is described a compound selected from the group consisting of tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof, for the treatment or alleviation of depression. There is also described a method of treating a patient suffering from depression.Type: ApplicationFiled: June 20, 2008Publication date: January 1, 2009Inventors: Malcolm Philip Young, Catherine Mary Yates, Olusola Clement Idowu, Julie Anne Charlton
-
Publication number: 20080262081Abstract: The use of resveratrol, a derivative, metabolite or analogue thereof, in combination with at least one additional component selected from EGCG, coenzyme Q-IO, genistein, lycopene, hydroxytyrosol and polyunsaturated fatty acids in the manufacture of a nutraceutical composition for delaying aging and/or for the treatment or prevention of age-related diseases in animals, in particular in mammals including humans.Type: ApplicationFiled: October 11, 2006Publication date: October 23, 2008Inventors: Daniel Raederstorff, Ying Wang-Schmidt, Swen Wolfram
-
Patent number: 7423026Abstract: The present invention is directed to novel complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of RM-?-cyclodextrin, DM-?-cyclodextrin and TM-?-cyclodextrin, and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrhydrocannabinol and cannabidiol.Type: GrantFiled: February 20, 2003Date of Patent: September 9, 2008Assignee: PediPharm OyInventors: Tomi Järvinen, Janne Mannila, Pekka Jarho
-
Publication number: 20080213319Abstract: The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.Type: ApplicationFiled: October 4, 2007Publication date: September 4, 2008Inventors: Hyun Kang, Scott Sacane, Jonathan L. Moon, Erica B. Goodhew, Lopa Bhatt, Stacey L. Rose, Milton H. Werner
-
Publication number: 20080199413Abstract: The present invention is directed to the use of a compound selected from the group consisting of ?-carotene, lutein, lycopene and ?-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including humans, for maintaining the respiratory function of the skin of animals including humans, for energizing the skin, maintaining and supporting the radiance and natural glow of the skin of animals including humans and for promoting a healthy appearance of the skin of animals including humans for preventing UV-A radiation-induced mtDNA mutagenesis in skin of animals including humans, as well as for the manufacture of a composition, preferably an orally applicable composition, for these uses and the corresponding methods.Type: ApplicationFiled: July 13, 2006Publication date: August 21, 2008Inventors: Regina Goralczyk, Karin Wertz
-
Publication number: 20080181955Abstract: A dietary supplement includes resveratrol in a therapeutically effective amount to permit release of nitric oxide (NO) during sexual stimulation and at least one polyphenol in a therapeutically effective amount to inhibit formation of type 5 phosphodiesterase (PDE-5). The dietary supplement is a dry powder derived from Muscadine grapes that are pressed and then stored at a temperature greater than 32° F. (0° C.) and less than 60° F. (15° C.) for at least 14 days. The pressed and stored grapes are dried and then ground into the dry powder. The concentration of the resveratrol is between 0.01 mg and 100 mg per 100 g of dry powder and the concentration of the polyphenol is between 0.04 mg and 400 mg per 100 g. A method for enhancing human libido includes providing the dry powder and consuming at least 50 mg of the dry powder daily for a period of at least 21 days.Type: ApplicationFiled: January 30, 2007Publication date: July 31, 2008Inventor: Lawrence X. Webb
-
Publication number: 20080171709Abstract: The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone and beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is antitumoral. The invention is for use in the field of pharmaceutics.Type: ApplicationFiled: May 15, 2006Publication date: July 17, 2008Applicant: ADVANCED SCIENTIFIC DEVELOPMENTSInventor: Adnane Remmal
-
Publication number: 20080160000Abstract: There is provided an animal feed, an anticoccidial agent, and an anticlostridial agent having less harm and an excellent prophylactic and/or therapeutic effect for coccidiosis and clostridial disease. Also provided is a prophylactic and/or therapeutic feed for coccidiosis containing pinene, thymol, eugenol, and limonene; an anticoccidial agent containing pinene, thymol, eugenol, and limonene as active ingredients; a clostridial disease prophylactic and/or therapeutic feed containing pinene, thymol, eugenol, and limonene; and an anticlostridial agent containing pinene, thymol, eugenol, and limonene as active ingredients.Type: ApplicationFiled: October 25, 2007Publication date: July 3, 2008Applicant: Marubeni Nisshin Feed Co., Ltd.Inventors: Yukihiro Motozono, Hiroyuki Suzuki, Kazuhiro Hatano, Masaaki Kise, Shinichi Horigome, Katsuhiro Mori, Yoshinaga Doi, Ryoji Koga
-
Publication number: 20080139667Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.Type: ApplicationFiled: June 7, 2005Publication date: June 12, 2008Applicant: GW Pharma LimitedInventors: Philip Robson, Geoffrey Guy
-
Publication number: 20080114058Abstract: The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a pharmaceutical composition for the treatment or prevention of an inflammatory disease, comprising a lignan compound represented by Formula I, as well as a treating method and the use of an inflammatory disease using the lignan compound. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-?. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.Type: ApplicationFiled: January 6, 2006Publication date: May 15, 2008Inventors: Jae-Kwan Hwang, Do-Un Kim, Jae-Youn Chung, Hee-Chul Chung, Kyu-Lee Han
-
Publication number: 20080103103Abstract: The invention provides compositions and methods of treating an ocular condition by administering to an eye of a patient having an ocular condition an effective amount of a catechin or polyphenol. The compositions and methods can be used to treat ocular conditions such as ocular infection, ocular inflammation, ocular cancer or benign eye tumors.Type: ApplicationFiled: October 30, 2006Publication date: May 1, 2008Inventors: Bahram Memarzadeh, Lyle Bowman
-
Publication number: 20080103107Abstract: The present invention provides materials and methods relating to screening for compounds useful in the treatment of Alzheimer's disease and related conditions. In particular, screening methods using tyrosine kinases are provided, as are methods relating to the role of tyrosine kinases as therapeutic targets.Type: ApplicationFiled: June 21, 2005Publication date: May 1, 2008Inventors: Malcolm Ward, Helen Byers, Brain Henry Anderton, Pascal Derkinderen, Christopher Hugh Reynolds, Ritchie Williamson
-
Patent number: 7364751Abstract: The present invention provides a reduced coenzyme Q-containing solution capable of being retained more stably against oxidation, by using a reduced coenzyme Q which is hydrophobic and susceptible to oxidation and thus unstable. The aqueous solution containing a reduced coenzyme Q obtained in the present invention is a solution containing a reduced coenzyme Q and an antioxidant such as vitamin C and/or a chelating agent such as ethylenediaminetetraacetic acid.Type: GrantFiled: October 10, 2002Date of Patent: April 29, 2008Assignee: Kaneka CorporationInventors: Kenji Fujii, Taizo Kawabe, Kazunori Hosoe, Takayoshi Hidaka
-
Publication number: 20080081078Abstract: Methods of using compounds having certain inhibitory effect to treat cancer are disclosed. More specifically, methods of using myosin light chain kinase inhibitor (MLCK) to treat cancer are disclosed. MLCK inhibitors may cause reduction in MLC-P and induce apoptosis in neoplastic cells and prevent and or inhibit the tumor growth.Type: ApplicationFiled: March 30, 2007Publication date: April 3, 2008Applicant: The Board of Trustees of the University of IllinoisInventor: Primal de Lanerolle
-
Publication number: 20070249596Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound.Type: ApplicationFiled: April 24, 2007Publication date: October 25, 2007Inventors: June Chen, Simon N. Pettit, Hans G. Fliri
-
Publication number: 20070249647Abstract: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.Type: ApplicationFiled: April 25, 2007Publication date: October 25, 2007Inventors: David L. Vander Jagt, Lorraine M. Deck
-
Publication number: 20070225360Abstract: An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the composition contains ascorbic acid, water is present as a co-solvent.Type: ApplicationFiled: March 20, 2007Publication date: September 27, 2007Applicant: L'OREALInventors: Sheldon R. Pinnell, Jan Zielinski, Isabelle Hansenne
-
Patent number: 7252845Abstract: Novel compositions of matter containing aromatic compounds and terpenoids which are present in and may preferably be derived from the plant Alpinia galanga (Zingiberaceae) show synergistic effects with respect to immunomodulation, and they significantly suppress hypersensitivity reactions. Thus they are used for preparing medicaments for these purposes and, more specifically, for the treatment or prevention of IgE mediated allergic reactions and conditions, such as asthma, allergic rhinitis, atopic eczema or anaphylaxis, and autoimmune disorders, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis or psoriasis, as well as for the alleviation of pain. They can for example be formulated into pharmaceuticals, cosmetics or dietary supplements. A method of preparing such compositions from Alpinia galanga is also described.Type: GrantFiled: January 2, 2003Date of Patent: August 7, 2007Assignee: Ferrosan A/SInventors: Morten Sloth Weidner, Morten Just Petersen, Nina Worm Jensen
-
Patent number: 7226610Abstract: Non-toxic, naturally derived and economical compositions for treating and preventing bacterial or fungal disease in plants, especially citrus canker, wherein such compositions include various combinations of d-limonene, wax and monohydric alcohol are provided. Methods for making and using such compositions are also provided.Type: GrantFiled: March 30, 2005Date of Patent: June 5, 2007Assignee: Preservation Sciences, Inc.Inventor: Paul Winniczuk
-
Patent number: 7205001Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: November 3, 2003Date of Patent: April 17, 2007Assignee: Polarx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Marmelstein
-
Patent number: 7163703Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: August 14, 2003Date of Patent: January 16, 2007Assignee: PolaRx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Mermelstein
-
Patent number: 7163961Abstract: The present invention provides a composition for preventing or treating diseases accompanied by a decrease in bone weight, hypertension and diseases resulting from hypertension, the composition containing, as an active component, at least one member selected from the a compound represented by formula (I) wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C1–C5 alkyl, sugar residue, —OR1, and —OCOR2; wherein R1 is selected from the group consisting of hydrogen, C1–C5 alkyl, hydroxy C1–C5 alkyl, and C2–C5 alkenyl; and R2 is selected from the group consisting of C1–C5 alkyl, hydroxy C1–C5 alkyl, and C2–C5 alkenyl; n is number of substituents A present and is a number from 0 to 5; and m is number of substituents B present and is a number from 0 to 5.Type: GrantFiled: January 28, 2000Date of Patent: January 16, 2007Assignee: Sunstar Inc.Inventors: Yukio Yamori, Katsumi Ikeda, Kenichi Mizutani, Yasuhiro Kawai
-
Patent number: 7153877Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: December 9, 2004Date of Patent: December 26, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7132116Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: August 14, 2003Date of Patent: November 7, 2006Assignee: PolaRx Biopharmaceuticals Inc.Inventors: Ralph M. Ellison, Fred H. Mermelstein
-
Patent number: 7125911Abstract: The autonomic nerve regulating agent of the present invention, which, has sedative action, sleep inducing action, and stress mitigating action in individuals, regardless of individual variation in sensitivity to or preference for fragrance, contains as an active ingredient a sesquiterpene alcohol with a boiling point of 250° C. or higher, particularly cedrol.Type: GrantFiled: October 10, 2001Date of Patent: October 24, 2006Assignee: Kao CorporationInventors: Yoshinao Nagashima, Keiichi Sugata, Yukihiro Yada, Kazuyuki Fukuda
-
Patent number: 7119110Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: October 4, 2002Date of Patent: October 10, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7094809Abstract: The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated tolan, particularly a polyhydroxylated tolan, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated tolan to a herpes virus-infected site. The present invention also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of treating a subject infected with Neisseria gonorrhea.Type: GrantFiled: June 11, 2003Date of Patent: August 22, 2006Assignees: Northeastern Ohio Universities College of Medicine, Kent State UniversityInventors: John Docherty, Chun-che Tsai
-
Patent number: 7037945Abstract: The present invention provides a method of inhibiting the formation of pseudorabies particles in a host cell. The method involves administering an effective amount of a poly-hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of reducing or inhibiting the growth of Neisseria gonorrhea and Neisseria meningiditis in vitro and in vivo. The method comprises administering a composition comprising a therapeutically effective amount of a tri-hydroxylated stilbene to a growth surface which has come into contact or could come into contact with the bacterium.Type: GrantFiled: December 11, 2001Date of Patent: May 2, 2006Assignee: Northeastern Ohio Universities College of MedicineInventor: John Docherty
-
Patent number: 6964969Abstract: A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body.Type: GrantFiled: April 19, 2001Date of Patent: November 15, 2005Inventor: Edward Larry McCleary
-
Patent number: 6956054Abstract: Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.Type: GrantFiled: August 14, 2002Date of Patent: October 18, 2005Assignees: Baylor University, OXiGENE, Inc.Inventors: Ronald W. Pero, David Sherris, Kevin G. Pinney, Vani P. Mocharla, Zhi Chen
-
Patent number: 6953786Abstract: Disclosed are methods for treating, preventing, or inhibiting cancer in a subject comprising administering at least one polyphenolic compound and at least one inhibitor of reactive oxygen species to the subject. The polyphenolic compound may be derived or isolated from plants. In some embodiments, the polyphenolic compound is a flavonoid. In other embodiments, the polyphenolic compound is a non-flavonoid. Other methods and kits are also disclosed as well as pharmaceutical compositions.Type: GrantFiled: October 1, 2002Date of Patent: October 11, 2005Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans' AffairsInventors: Stephen J. Pandol, Anna Gukovskaya
-
Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
Patent number: 6949582Abstract: A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.Type: GrantFiled: September 13, 2002Date of Patent: September 27, 2005Inventor: Walter H. Wallace -
Patent number: 6943196Abstract: An NF-?B inhibitor having as an active ingredient a benzoquinone derivative represented by the general formula (1) wherein R1, R2, and R3 are each independently H, alkyl having 1 to 5 carbons, or alkoxy having 1 to 5 carbons; R4 is H, hydroxymethyl, alkyl, or carboxyl which is optionally esterified or amidated; Z is represented by the formula (A); and, n is an integer from 0 to 6, or its hydroquinone form or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 19, 1999Date of Patent: September 13, 2005Assignee: Daiichi Suntory Pharma Co., Ltd.Inventors: Yoichi Nunokawa, Kenji Suzuki, Masayuki Saitoh
-
Patent number: 6878751Abstract: A method is provided for treating inflammatory respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The method involves administration, preferably oral or pulmonary administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.Type: GrantFiled: October 19, 2000Date of Patent: April 12, 2005Assignees: Imperial College of Science Technology and Medicine, Imperial College Innovations LimitedInventors: Louise Elizabeth Donnelly, Peter John Barnes
-
Patent number: 6875451Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: October 15, 1998Date of Patent: April 5, 2005Assignee: PolaRx Biopharmaceuticals Inc.Inventors: Ralph M. Ellison, Fred H. Mermelstein
-
Patent number: 6841577Abstract: A pesticide for cockroaches and larvae which is based on purified naturally occurring plant substances. Phenethyl propionate; methyl salicylate; pulegone; carvacrol; thymol; thyme oil; citronellal; a three-blend of eugenol, ?-terpineol and cinnamic alcohol; a four-blend of benzyl alcohol, phenethyl alcohol, phenethyl propionate and ?-terpineol; and a five-blend of thymol, t-anethole, ?-terpineol, eugenol and citronellal have been used as the pesticide. The pesticide affects the octopamine receptor site in the cockroach. The five-blend has been used as a pesticide for Asian armyworms and green peach aphid nymphs. Methods of use of the pesticides are disclosed.Type: GrantFiled: December 18, 2001Date of Patent: January 11, 2005Assignee: Ecosmart Technologies, Inc.Inventors: Steven M. Bessette, Myron A. Beigler
-
Publication number: 20040259816Abstract: Disclosed are methods for treating, preventing, or inhibiting diseases and disorders associated with NF-&kgr;B activation including proliferative diseases such as cancer and inflammatory diseases such as pancreatitis in a subject which comprises administering at least one polyphenolic compound and/or at least one inhibitor of reactive oxygen species to the subject. Also disclosed are pharmaceutical compositions comprising at least one polyphenolic compound and/or at least one inhibitor of reactive oxygen species. The polyphenolic compound may be derived or isolated from plants. In some embodiments, the polyphenolic compound is a flavonoid. In other embodiments, the polyphenolic compound is a non-flavonoid. Other methods and kits are also disclosed as well as pharmaceutical compositions.Type: ApplicationFiled: April 15, 2004Publication date: December 23, 2004Inventors: Stephen J. Pandol, Anna Gukovskaya, Moussa Yazbeck, Guido Eibl, Laszlo G. Boros
-
Publication number: 20040242696Abstract: Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.Type: ApplicationFiled: March 1, 2004Publication date: December 2, 2004Inventors: David J. Chaplin, Klaus Edvardsen, Kevin G. Pinney, Joseph Anthony Prezioso, Mark Wood
-
Publication number: 20040242500Abstract: The invention provides compositions and methods, for reducing one or more symptoms of an autoimmune disease, inflammatory disease and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount purified compound of any one of Formulae A-E. The invention's method are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection.Type: ApplicationFiled: April 30, 2004Publication date: December 2, 2004Inventor: Michael David
-
Patent number: 6814960Abstract: The use of hydroxystilbene compounds of formula wherein A is a radical of formula or a radical of formula and R1, R2, R3, R4 and R5 are each independently of the others hydrogen, halogen, hydroxy, C1-C16alkyl, C1-C16alkoxy, phenyl; C1-C3phenylalkyl; C6-C10aryloxy, amino, mono-C1-C5alkylamino, di-C1-C5alkylamino, or —NO2; as microbicidal active ingredients is described. The compounds exhibit a pronounced action against pathogenic gram-positive and gram-negative bacteria, and also against yeasts and moulds. They are therefore suitable for the antimicrobial treatment, especially the preservation and disinfection, of surfaces.Type: GrantFiled: April 5, 2001Date of Patent: November 9, 2004Assignee: Ciba Specialty Chemicals CorporationInventors: Werner Hölzl, Dietmar Ochs, Wolfgang Haap, Karin Puchtler, Marc I Schnyder
-
Publication number: 20040209951Abstract: This invention relates to novel resveratrol analogs of the formula given below; wherein R, R1, R2 and R3 are: 1. R=OH, R1=R2=R3=H; 2. R=OH, R1=Br, R2=R3=H; 3. R=R1=OH, R2=R3=H; 4. R=R1=R3=H, R2=3,4,5-trihydroxybenzoyl; 5. R=R1=H, R2=R3=3,4,5-trihydroxybenzoyl; 6. R=R1=R3=H, R2=3,4-dihydroxycinnamoyl; 7. R=R1=R3=H, R2=3,4,5-trihydroxycinnamoyl; 8. R=R1=R3=H, R2=—CH2CH2N(CH3)2; 9. R=R1=R3=H, R2=—COCH2NH2.HCl. These compounds exhibited high antioxidant properties and are useful in food industry and in cosmetics. The compounds may be used in pharmaceutical composition as an antioxidant or free radical scavenger.Type: ApplicationFiled: February 13, 2004Publication date: October 21, 2004Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Subbaraju Gottumukkala, Venkateswarlu Somepalli
-
Publication number: 20040176311Abstract: A composition and an associated method of treating cancer cells by impeding cancer cell growth with the composition are disclosed. The composition includes at least a first and a second HMG-CoA reductase inhibitor, wherein the total amount of the first and second HMG-CoA reductase inhibitors is effective in synergistically impeding cancer cell growth and wherein the cancer cell growth synergistic impedance from the total amount of the first and second HMG-CoA reductase inhibitors is greater than a theoretical additive effect from the combined first and second HMG-CoA reductase inhibitors. The present composition does not simultaneously contain both a tocotrienol and an ionone when the composition contains only a first and a second HMG-CoA reductase inhibitor. The method includes treating cancer cells with the claimed composition to impede cancer cell growth.Type: ApplicationFiled: March 7, 2003Publication date: September 9, 2004Inventors: Huanbiao Mo, Charles E. Elson, Dennis M. Peffley, Patricia M. Hentosh
-
Patent number: 6773702Abstract: A method of treating immune suppression in a warm-blooded animal bearing a tumor, by administering to the animal an amount of combretastatin A4 and/or a prodrug thereof effective to enhance immune responsiveness without causing vascular destruction. Immunotherapy treatment to inhibit or kill tumor cells includes administering to the animal an immune-response-stimulating agent such as a vaccine of tumor cells genetically modified to produce an immune-response-enhancing cytokine while counteracting tumor-induced immune suppression in the animal by administering combretastatin A4 and/or a prodrug thereof.Type: GrantFiled: December 26, 2001Date of Patent: August 10, 2004Assignees: OXiGENE, Inc., Bristol-Myers Squibb CompanyInventors: Ronald W. Pero, Francis Y. F. Lee, Klaus Edvardsen, Hans Olov Sjögren
-
Patent number: 6753000Abstract: Cosmetic/dermatological compositions, well suited, e.g., for skin-firming and anti-aging applications, as well as for stimulating the proliferation of dermal fibroblasts, comprise effective skin affliction-alleviating amounts of (a) at least one hydroxystilbene compound, in immixture with (b) at least one ascorbic acid compound, advantageously formulated into a topically applicable, physiologically/cosmetically acceptable vehicle, diluent or carrier therefor.Type: GrantFiled: August 19, 2002Date of Patent: June 22, 2004Assignee: L'OrealInventors: Lionel Breton, Christel Liviero
-
Patent number: 6733764Abstract: The present invention comprises a method for the treatment of cancerous tumors in mammals comprising the administration of an effective amount of an immunostimulator which enhances and potentiates the mammals own immune system to selectively attack and kill the cancerous cells. The immunostimulator, preferably urushiol, is administered in a pharmaceutically acceptable carrier and can be co-administered in conjunction with other immunostimulators, radiation therapy or other cytotoxic anti-cancer agents to further enhance their effect.Type: GrantFiled: June 11, 2001Date of Patent: May 11, 2004Inventor: Alain Martin
-
Patent number: 6730294Abstract: A method of forming a water soluble biocidal film on a solid household, food preparation, or medical surface, which protects the solid surface against reinfection by microorganisms, includes providing a liquid biocidal composition comprised of, based on total weight of the liquid biocidal composition from 0.1 to 5.0 wt. % of a phenolic biocide; from an amount effective to impart film-forming properties to the liquid biocidal composition up to 8 wt. % of a polyvinyl pyrrolidone polymer or copolymer; and an aqueous alcoholic solvent in which the phenolic biocide and the polyvinylpyrrolidone polymer or copolymer are dissolved; treating the solid surface with the liquid biocidal composition; and evaporating the aqueous alcoholic solvent to provide a clear film, wherein a ratio of the phenolic biocide to the polyvinylpyrrolidone polymer or copolymer is selected to range from 1:0.8 to 1:3 so that a complex there between is provided which dries clear.Type: GrantFiled: March 31, 2000Date of Patent: May 4, 2004Assignee: Novapharm Research (Australia) Pty LimitedInventor: Steven Kritzler